• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
In vitro activity of ceftriaxone, cefetamet (Ro 15-8074), ceftetrame (Ro 19-5247; T-2588), and fleroxacin (Ro 23-6240; AM-833) versus Neisseria gonorrhoeae and Haemophilus ducreyi.头孢曲松、头孢他美酯（Ro 15 - 8074）、头孢替安酯（Ro 19 - 5247；T - 2588）及氟罗沙星（Ro 23 - 6240；AM - 833）对淋病奈瑟菌和杜克雷嗜血杆菌的体外活性
Antimicrob Agents Chemother. 1987 Jul;31(7):1153-4. doi: 10.1128/AAC.31.7.1153.
2
The activity of the 4 quinolone Ro 23 6240 and the cephalosporins Ro 15 8074 and Ro 19 5247 against penicillin sensitive and resistant gonococci.4-喹诺酮Ro 23 6240以及头孢菌素Ro 15 8074和Ro 19 5247对青霉素敏感和耐药淋球菌的活性。
J Antimicrob Chemother. 1987 Jun;19(6):761-5. doi: 10.1093/jac/19.6.761.
3
In vitro activity of RO 15-8074 and RO 19-5247.RO 15 - 8074与RO 19 - 5247的体外活性
Eur J Clin Microbiol. 1987 Apr;6(2):167-9. doi: 10.1007/BF02018201.
4
Activity of Ro 236240, Ro 158074 and Ro 195247 against resistant gonococci.Ro 236240、Ro 158074和Ro 195247对耐药淋球菌的活性。
Chemioterapia. 1987 Jun;6(2 Suppl):156.
5
In vitro activity of Ro 15-8074, Ro 19-5247, A-56268, and roxithromycin (RU 28965) against Neisseria gonorrhoeae and Chlamydia trachomatis.Ro 15 - 8074、Ro 19 - 5247、A - 56268及罗红霉素（RU 28965）对淋病奈瑟菌和沙眼衣原体的体外活性。
Antimicrob Agents Chemother. 1987 Mar;31(3):470-2. doi: 10.1128/AAC.31.3.470.
6
In vitro activity of the new quinolone RO 23-6240 (AM-833) and the new cephalosporins RO 15-8074 and RO 19-5247 (T-2525) against Mycobacterium fortuitum and Mycobacterium chelonae.新型喹诺酮RO 23-6240（AM-833）以及新型头孢菌素RO 15-8074和RO 19-5247（T-2525）对偶然分枝杆菌和龟分枝杆菌的体外活性
Eur J Clin Microbiol. 1987 Aug;6(4):487-8. doi: 10.1007/BF02013118.
7
In vitro activity and beta-lactamase stability of two oral cephalosporins, ceftetrame (Ro 19-5247) and cefetamet (Ro 15-8074).两种口服头孢菌素头孢替胺（Ro 19-5247）和头孢他美酯（Ro 15-8074）的体外活性及β-内酰胺酶稳定性
Antimicrob Agents Chemother. 1986 Sep;30(3):423-8. doi: 10.1128/AAC.30.3.423.
8
Comparative in vitro antibacterial activities of two new oral cephalosporins, ceftetrame (Ro 19-5247) and cefetamet (Ro 15-8074).两种新型口服头孢菌素头孢替姆（Ro 19-5247）和头孢他美酯（Ro 15-8074）的体外抗菌活性比较
Antimicrob Agents Chemother. 1987 Mar;31(3):473-6. doi: 10.1128/AAC.31.3.473.
9
Emergence of decreased susceptibility to extended-spectrum cephalosporins in Neisseria gonorrhoeae in India.印度淋病奈瑟菌对超广谱头孢菌素敏感性降低的情况出现。
Natl Med J India. 2013 Jan-Feb;26(1):26-8.
10
In-vitro activity of azithromycin, erythromycin, ciprofloxacin and norfloxacin against Neisseria gonorrhoeae, Haemophilus ducreyi, and Chlamydia trachomatis.
J Antimicrob Chemother. 1990 Jan;25 Suppl A:1-5. doi: 10.1093/jac/25.suppl_a.1.

引用本文的文献

1
Cefetamet pivoxil clinical pharmacokinetics.头孢他美酯的临床药代动力学。
Clin Pharmacokinet. 1993 Sep;25(3):172-88. doi: 10.2165/00003088-199325030-00002.
2
Cefetamet pivoxil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.头孢他美酯。其抗菌活性、药代动力学特性及治疗用途综述。
Drugs. 1993 Apr;45(4):589-621. doi: 10.2165/00003495-199345040-00009.
3
Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections.氟罗沙星。对其在各种感染中的药理学及治疗效果的综述。
Drugs. 1995 May;49(5):794-850. doi: 10.2165/00003495-199549050-00010.
4
Fluoroquinolone antimicrobial agents.氟喹诺酮类抗菌剂。
Clin Microbiol Rev. 1989 Oct;2(4):378-424. doi: 10.1128/CMR.2.4.378.
5
Evaluation of fleroxacin (RO 23-6240) as single-oral-dose therapy of culture-proven chancroid in Nairobi, Kenya.在肯尼亚内罗毕，对氟罗沙星（RO 23 - 6240）作为经培养证实的软下疳单剂量口服疗法进行评估。
Antimicrob Agents Chemother. 1989 May;33(5):612-4. doi: 10.1128/AAC.33.5.612.
6
Antimicrobial susceptibility of Haemophilus ducreyi.杜克雷嗜血杆菌的抗菌药敏性。
Antimicrob Agents Chemother. 1990 Jul;34(7):1303-7. doi: 10.1128/AAC.34.7.1303.
7
Fleroxacin clinical pharmacokinetics.氟罗沙星的临床药代动力学。
Clin Pharmacokinet. 1992 Feb;22(2):116-31. doi: 10.2165/00003088-199222020-00003.
8
Correlation between in vitro antimicrobial susceptibilities and beta-lactamase plasmid contents of isolates of Haemophilus ducreyi from the United States.美国杜克雷嗜血杆菌分离株的体外抗菌药敏性与β-内酰胺酶质粒含量之间的相关性
Antimicrob Agents Chemother. 1992 Aug;36(8):1639-43. doi: 10.1128/AAC.36.8.1639.

本文引用的文献

1
Gonococcal strains from homosexual men have outer membranes with reduced permeability to hydrophobic molecules.来自同性恋男性的淋病菌株具有对疏水分子通透性降低的外膜。
Infect Immun. 1982 Aug;37(2):432-8. doi: 10.1128/iai.37.2.432-438.1982.
2
Antimicrobial therapy of chancroid: an evaluation of five treatment regimens correlated with in vitro sensitivity.软下疳的抗菌治疗：五种治疗方案与体外敏感性相关性的评估
Sex Transm Dis. 1983 Jan-Mar;10(1):1-6.
3
The plasmids of Haemophilus ducreyi.杜克雷嗜血杆菌的质粒
J Antimicrob Chemother. 1984 Dec;14(6):561-4.
4
In vitro antimicrobial activity of eight new beta-lactam antibiotics against penicillin-resistant Neisseria gonorrhoeae.八种新型β-内酰胺抗生素对耐青霉素淋病奈瑟菌的体外抗菌活性。
Antimicrob Agents Chemother. 1983 Apr;23(4):541-4. doi: 10.1128/AAC.23.4.541.
5
In vitro activity of Ro 15-8074, a new oral cephalosporin, against Neisseria gonorrhoeae.新型口服头孢菌素Ro 15-8074对淋病奈瑟菌的体外活性
Antimicrob Agents Chemother. 1985 Sep;28(3):461-3. doi: 10.1128/AAC.28.3.461.
6
Antimicrobial susceptibility testing and phenotyping of Neisseria gonorrhoeae isolated from patients with ophthalmia neonatorum in Nairobi, Kenya.对从肯尼亚内罗毕新生儿眼炎患者中分离出的淋病奈瑟菌进行药敏试验和表型分析。
Antimicrob Agents Chemother. 1985 Sep;28(3):393-6. doi: 10.1128/AAC.28.3.393.
7
Gonococcal infections.淋病感染。
Ann Intern Med. 1985 Feb;102(2):229-43. doi: 10.7326/0003-4819-102-2-229.
8
Genetics of resistance in a non-beta-lactamase-producing gonococcus with relatively high-level penicillin resistance.具有相对高水平青霉素抗性的非β-内酰胺酶产生型淋球菌的抗性遗传学
Antimicrob Agents Chemother. 1986 Dec;30(6):856-60. doi: 10.1128/AAC.30.6.856.

头孢曲松、头孢他美酯（Ro 15 - 8074）、头孢替安酯（Ro 19 - 5247；T - 2588）及氟罗沙星（Ro 23 - 6240；AM - 833）对淋病奈瑟菌和杜克雷嗜血杆菌的体外活性

In vitro activity of ceftriaxone, cefetamet (Ro 15-8074), ceftetrame (Ro 19-5247; T-2588), and fleroxacin (Ro 23-6240; AM-833) versus Neisseria gonorrhoeae and Haemophilus ducreyi.

作者信息

Le Saux N M, Slaney L A, Plummer F A, Ronald A R, Brunham R C

机构信息

Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada.

出版信息

Antimicrob Agents Chemother. 1987 Jul;31(7):1153-4. doi: 10.1128/AAC.31.7.1153.

DOI:10.1128/AAC.31.7.1153
PMID:2959199
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC174890/
Abstract

We examined 300 strains of Neisseria gonorrhoeae and 100 strains of Haemophilus ducreyi to determine their in vitro susceptibility to two new cephalosporins, cefetamet (Ro 15-8074) and ceftetrame (Ro 19-5247; T-2588), and a new fluroquinolone, fleroxacin (Ro 23-6240; AM-833). Their activity was compared with that of ceftriaxone, penicillin, spectinomycin, tetracycline, and erythromycin. Cefetamet, ceftetrame, and fleroxacin had excellent in vitro activity against both groups of microorganisms. beta-Lactamase production did not significantly affect the MICs of these agents. The Mtr phenotype of N. gonorrhoeae raised the MICs two- to fourfold, but the MICs remained within the range of achievable levels in serum. These newer compounds have a distinct advantage over existing therapeutic agents in that they can be administered orally. Clinical trials are warranted to assess their usefulness in the therapy of gonorrhea and chancroid.

摘要

我们检测了300株淋病奈瑟菌和100株杜克雷嗜血杆菌，以确定它们对两种新型头孢菌素（头孢他美酯（Ro 15 - 8074）和头孢曲嗪（Ro 19 - 5247；T - 2588））以及一种新型氟喹诺酮类药物（氟罗沙星（Ro 23 - 6240；AM - 833））的体外敏感性。并将它们的活性与头孢曲松、青霉素、壮观霉素、四环素和红霉素进行了比较。头孢他美酯、头孢曲嗪和氟罗沙星对这两组微生物均具有优异的体外活性。β - 内酰胺酶的产生对这些药物的最低抑菌浓度（MIC）没有显著影响。淋病奈瑟菌的Mtr表型使MIC提高了两到四倍，但MIC仍处于血清中可达到的水平范围内。这些新型化合物相对于现有治疗药物具有明显优势，因为它们可以口服给药。有必要进行临床试验以评估它们在淋病和软下疳治疗中的有效性。